EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Evaluation of the effect of erenumab on migraine‐specific questionnaire in patients with chronic and episodic migraine

Po-Wei Chen, Mats O Karlsson iD, Sebastian Ueckert iD, Ari Pritchard-Bell, Cheng-Pang Hsu, Sandeep Dutta, Malidi Ahamadi

CPT: Pharmacometrics & Systems Pharmacology · 2023

DOI: 10.1002/psp4.13048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2023. Verfasst von Po-Wei Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Modeling and Simulation, Amgen Inc., Thousand Oaks, California, USA. Hauptthemen laut MEDLINE: Quality of Life, Migraine Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AMGEN Inc., Amgen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Erenumab is a fully human anti‐canonical calcitonin gene‐related peptide receptor monoclonal antibody approved for migraine prevention. The Migraine‐Specific Quality‐of‐Life Questionnaire (MSQ) is a 14‐item patient‐reported outcome instrument that measures the impact of migraine on health‐related quality of life. Erenumab data from four phase II/III clinical trials were used to develop an item response theory (IRT) model within a nonlinear mixed effects framework, (i) evaluate the MSQ item information with respect to patient disability, (ii) characterize the longitudinal progression of the MSQ, and (iii) quantify the effect of erenumab on the MSQ in patients with migraine. The majority (80%) of information was found to be contained in 9 out of 14 items, extending the current knowledge on the reliability of the MSQ as a psychometric tool. Simulations across three MSQ domains show significant improvement from baseline, exceeding minimally important differences. Overall, the IRT model platform developed herein allows for systematic quantification of the effect of erenumab on the MSQ in patients with migraine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeMigraine DisordersHumansReproducibility of ResultsSurveys and QuestionnairesAntibodies, Monoclonal, Humanized

Substanzen

erenumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Clinical Pharmacology Modeling and Simulation, Amgen Inc., Thousand Oaks, California, USA.
  • Department of Pharmacy, Uppsala University, Uppsala, Sweden.
  • AskGene Pharma Inc., Camarillo, California, USA.

ORCID-Profile: Mats O Karlsson, Sebastian Ueckert

Förderung

  • AMGEN Inc.
  • Amgen

Zitieren

APA

Chen, P. W., Karlsson, M. O., Ueckert, S., Pritchard-Bell, A., Hsu, C. P., Dutta, S., & Ahamadi, M. (2023). Evaluation of the effect of erenumab on migraine‐specific questionnaire in patients with chronic and episodic migraine. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13048

Vancouver

Chen PW, Karlsson MO, Ueckert S, Pritchard-Bell A, Hsu CP, Dutta S, et al. Evaluation of the effect of erenumab on migraine‐specific questionnaire in patients with chronic and episodic migraine. CPT: Pharmacometrics & Systems Pharmacology. 2023. doi:10.1002/psp4.13048

BibTeX
@article{Chen2023,
  author = {Chen, Po-Wei and Karlsson, Mats O and Ueckert, Sebastian and Pritchard-Bell, Ari and Hsu, Cheng-Pang and Dutta, Sandeep and Ahamadi, Malidi},
  title = {Evaluation of the effect of erenumab on migraine‐specific questionnaire in patients with chronic and episodic migraine},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2023},
  doi = {10.1002/psp4.13048}
}
Kostenlos starten →